Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MLNR | O43193 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6817248 | 1.00 | HTR6 (0.39) | HTR6MEN1KMT2ACYP2D6ALDH1A1 | |
| SCHEMBL616084 | 1.00 | HTR6 (0.39) | HTR6MEN1KMT2ACYP2D6ALDH1A1 | |
| SCHEMBL4023649 | 1.00 | HTR6 (0.39) | HTR6MEN1KMT2ACYP2D6ALDH1A1 | |
| SCHEMBL1181468 | 0.98 | HTR6 (0.40) | HTR6MEN1KMT2ACYP2D6ALDH1A1 | |
| SCHEMBL22628194 | 0.98 | HTR6 (0.40) | HTR6MEN1KMT2ACYP2D6ALDH1A1 | |
| SCHEMBL548524 | 0.95 | HTR6 (0.39) | HTR6MEN1KMT2ACYP2D6ALDH1A1 | |
| SCHEMBL9632289 | 0.93 | KDM4E (0.38) | HTR6MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL28210606 | 0.93 | MEN1 (0.36) | HTR6MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1202752 | 0.93 | MEN1 (0.36) | HTR6MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL9388849 | 0.93 | HTR6 (0.40) | HTR6MEN1KMT2ACYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024216732-A1 | METHOD FOR PREPARING PYRIDINE COMPOUND WITH META POSITION THEREOF SUBSTITUTED BY CHIRAL ALLYL | 南开大学 | 2024-10-24 | — | — | WO | disclosed |
| CN-111269338-B | Chelate resin with 4-piperidyl piperidine as ligand and preparation method and application thereof | 台州学院 | 2021-04-13 | — | — | CN | disclosed |
| EP-3087077-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2018-10-31 | — | — | EP | disclosed |
| US-9839629-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160324833-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2016-11-10 | — | — | US | disclosed |
| EP-3087077-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015100147-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015096035-A1 | INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | WO | disclosed |
| EP-1740570-A2 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006102308-A2 | BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060004004-A1 | Novel gamma secretase inhibitors | SCHERING CORPORATION | 2006-01-05 | — | — | US | disclosed |
| WO-2005097768-A2 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004004-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | HTR6 4086/4885MEN1 4191/4885KMT2A 2876/4885 |
| US-20160324833-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, WNK1, KCNJ1 | HTR6 2796/4885MEN1 383/4885KMT2A 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.